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This study’s aim was to determine the relationship between Dermatology Life Quality Index (DLQI) scores and a
Global Question (GQ) concerning patients’ views of the overall impairment of their skin-related quality of life (QoL),
and to express this relationship by identifying bands of DLQI scores equivalent to each GQ descriptor. A DLQI
questionnaire and the GQ were mailed to 3834 adult general dermatology outpatients. There were 1993 (52%)
responses: male 841; female 1152. Mean DLQI score¼ 4.86 (range 0–30, standard deviation (SD)¼ 5.83). Mean GQ
score¼ 1.22 (range 0–4, SD¼ 1.20). The mean, mode, and median of the GQ scores for each DLQI score were used
to devise several sets of bands of DLQI scores, and j coefﬁcients of agreement calculated. The set proposed for
adoption is: DLQI scores 0–1¼no effect on patient’s life (GQ¼ 0, n¼ 754); DLQI scores 2–5¼ small effect on
patient’s life (GQ¼ 1, n¼ 611); DLQI scores 6–10¼moderate effect on patient’s life (GQ¼ 2, n¼ 327); DLQI scores
11–20¼ very large effect on patient’s life (GQ¼ 3, n¼ 242); DLQI scores 21–30¼ extremely large effect on patient’s
life (GQ¼ 4, n¼ 59); j coefﬁcient 0.489. Banding of the DLQI will aid the clinical interpretation of an individual’s
DLQI score and allow DLQI scores to inform clinical decisions.
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Health-related quality of life (HRQoL) measurement assess-
es burden of illness and allows assessment of the outcomes
of medical treatments (Calman, 1984; Price and Harding,
1993; Finlay, 1997). It can be defined as the subjective per-
ception of the impact of health status, including disease and
treatment, on physical, psychological, and social well-be-
ing. HRQoL in skin patients may be assessed using generic
or specific HRQoL instruments (Bergner et al, 1981; Finlay
and Kelly, 1987; Finlay and Khan, 1994). Validated derma-
tology-specific instruments include the Dermatology Life
Quality Index (DLQI); Dermatology Quality of Life Scales;
and Dermatology Specific Quality of Life and Skindex (Fin-
lay and Khan, 1994; Chren et al, 1996; Anderson and Ra-
jagopalan, 1997; Morgan et al, 1997). The DLQI is concise
and user-friendly with only ten questions (Finlay and Khan,
1994) (see Fig 1). Its reliability and validity have been dem-
onstrated (Zachariae et al, 2000; Hahn et al, 2001; Mork
et al, 2002) and it has been used in over 137 studies in 20
countries (Lewis and Finlay, 2004).
Although high DLQI scores equate to high HRQoL im-
pairment, interpretation of the clinical meaning of the scores
is not adequately researched for the DLQI or for other der-
matology HRQoL measurement techniques and this is a
significant issue in dermatology (Schiffner et al, 2003). The
lack of such information in dermatology is in contrast to
other areas of medicine such as oncology (Osoba, 2002),
spinal cord injury (May and Warren, 2001), and hematology
(Gulbrandsen et al, 2004). Assessment of the ‘‘meaningful-
ness’’ of DLQI scores is essential if clinicians are to be able
to use such measures as an aid to decision taking in patient
management. It has been demonstrated that DLQI scores
do change significantly if the clinical activity of psoriasis
changes and that in psoriasis the DLQI can detect small but
meaningful changes in clinical status over time (Mazzotti
et al, 2003). This study uses an anchor question approach in
order to establish ranges of scores reflecting patients’ glo-
bal rating of quality of life (QoL); this is considered an es-
sential first step before addressing the question of minimal
important difference.
It is believed that the examination of the relationship be-
tween DLQI scores and patients’ view of their overall impair-
ment of HRQoL will enhance dermatologists’ understanding
of the application of HRQoL outcomes in clinical practice.
Results
From the 3834 patients who were posted the study pack,
there were 1993 (52.0%) evaluable responses. Of these
1712 were on the waiting list (WL) and 281 had already been
seen in outpatients (AS). The demographic details of those
patients who had already been seen were very similar to
those patients who were still on the WL. The only significant
difference between these sub-groups was in the mean DLQI
(WL¼4.70, AS¼ 5.79, p¼0.0012) and mean Global Ques-
tion (GQ) (WL¼1.18, AS¼1.48, po0.0005) scores.
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The 1993 responders comprised 841 men and 1152
women, with a mean age of 57.5 y (age range 16–98 y,
standard deviation (SD) 19.4). The non-responders com-
prised 706 men and 1135 women; therefore, 54.4% of the
men sent a study pack responded whereas only 50.4% of
the women responded. The ages of the non-responders
were very similar to that of the responders (mean age of
non-responders 50.3 y, SD 18.9).
The overall mean DLQI score was 4.86 (range 0–30, SD
5.83) and the mean GQ score was 1.22 (range 0–4, SD
1.20). The mean DLQI score for men (4.93, SD¼5.74) was
similar to that for women (4.81 SD¼5.88), as was the mean
GQ score (men 1.24, SD¼1.15; women 1.21, SD¼ 1.25).
The Mann–Whitney U test also showed no significant dif-
ference between men and women for either the DLQI or
GQ scores (Pv¼ 0.266 and Pv¼0.143, respectively). The
Spearman rank correlation coefficient showed a strong cor-
relation between the DLQI scores and the GQ scores
(r¼0.83, po0.01).
For each score of the DLQI from 0 to 30, the number of
patients with that score and their corresponding GQ score is
shown in Table I. Figure 2 and Table I show the mode, mean,
and median of the GQ scores for each DLQI score, and
these were used as the basis for grouping the DLQI scores
together into a set of five discrete bands, so that each band
would correspond to a single GQ score. There are a few
DLQI scores that could possibly be included in either of the
two adjacent bands, such as DLQI scores of 11 and 12
could either be in the band corresponding to a GQ of 2, or in
the GQ of 3 band. Similarly, DLQI scores of 21 and 22 could
either be included in the GQ of 3 band, or in the GQ of 4
band. Separate sets of bands were therefore produced with
different groupings of DLQI scores, and the k coefficient of
agreement calculated for each set of bands (Table II). These
bands also emphasize the non-linear nature of the DLQI, a
common characteristic of QoL measures. The k coefficient
is a measure of the level of agreement beyond that which
could be expected by chance. The maximum level of
agreement is a k of 1.0, and values of 0.41–0.60 are con-
sidered a moderate strength of agreement (Altman, 1991).
The set of bands with the highest k coefficient (0.493)
was 0–1, 2–5, 6–12, 13–20, and 21–30. Another set of bands
examined (0–1, 2–5, 6–10, 11–20, 21–30, Table III) had al-
most as high a k coefficient, 0.489, and has in addition other
merits that support this banding system being adopted for
interpretation of DLQI scores in the general outpatient set-
ting. The effect, and perhaps one of the advantages, of
choosing this banding (Table III) compared with the banding
with the highest k score is to move 4% of the total study
population from band 2 to band 3.
Subgroup analysis Considering the data (Table III) de-
scribing the proposed set of bands (0–1, 2–5, 6–10, 11–20,
21–30), there were a total of 59 patients whose actual GQ
score was 2 or more points higher than the DLQI band
would have predicted from their DLQI score. In contrast,
there were only 18 patients whose actual GQ score was 2 or
more points lower than predicted. All the patients whose
GQ scores were 2 or more points away from the banding
allocation were compared with those patients whose GQ
scores agreed with the DLQI banding by carrying out a sub-
score analysis of the ten individual questions on the DLQI,
and also by observing whether they had hand-written any
comments on their questionnaire replies. There were five
questionnaires (8.5%) out of the 59 patients with high GQ
scores that had hand-written comments upon them. Two of
these patients had written that they were very worried that
their skin complaint might be cancer. These two patients
had scored 0 and 1 on the DLQI, but had scored 4 and 2,
respectively, on the GQ. There is no question on the DLQI
that asks about patients’ concerns regarding future health.
The sub-score comparison was carried out within each
DLQI band (Appendix 1 online and Table SI). There was no
single DLQI question that was consistently related to high
GQ scores.
Dermatological conditions The 1108 referral letters analy-
zed for probable dermatological diagnosis revealed the fol-
lowing case distribution: 251 (22.7%) non-melanoma skin
cancers and pre-malignant lesions; 234 (21.1%) benign skin
and vascular tumors; 112 (10.1%) benign pigmented lesions
and naevi; 108 (9.7%) eczematous conditions; 99 (8.9%)
cases of acne and other disorders of sebaceous, apocrine
and eccrine glands; 68 (6.1%) viral skin lesions; 60 (5.4%)
psoriasis; 29 (2.6%) hair and scalp disorders; 20 keloid
scars; 18 genital skin disorders; 18 pigmentary disorders;
17 urticarial disorders; 16 nail disorders; 15 superficial fun-
gal infections; 12 pruritus; 11 reactive skin disorders and
drug reactions; eight skin manifestations of possible endo-
crine disease; six purely bacterial infections; three scabies
or lice infestations; two psychological skin disorders; and
one immunobullous skin disease. Because of local referral
practices, there were no patients with leg ulcers on the WL.
Patients with suspected melanoma are not put on the WL.
Discussion
There has been great interest in the measurement of HRQoL
in dermatology in recent years (Finlay, 2001). Although the
reliability and validity of many disease-specific and derma-
tology-specific HRQoL instruments have been established
Figure 1
The Dermatology Life Quality Index (Finlay and Khan, 1994).
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through clinical studies, they are not yet accepted in clinical
practice. Assessment of the meaning of scores of each in-
strument is the most important current challenge, beyond
simply meeting the conventional psychometric require-
ments. Unfortunately, basic information about interpreta-
tion of the scores is not adequate either for the DLQI or for
other HRQoL instruments and this area remains controver-
sial (Testa, 2000). The concise format of the DLQI has
facilitated this attempt at exploring HRQoL meaning in
dermatology. Composite scores for QoL measures do suf-
fer from inherent limitations and weaknesses; generalizabil-
ity of scores should also be interpreted with caution, in
particular when scores are related to individual patients. The
purpose of this study, however, was to establish ranges by
which to make overall scores more meaningful and thereby
add to the information that can be gained by looking at
the detailed sub-score profiles within the DLQI. It is not
suggested that this approach dilutes the importance of
Table I. Numbers of patients with each DLQI score and details of the corresponding GQ score, with the mean, mode, and median
of the GQ scores
DLQI score
GQ score
Patient totals0 1 2 3 4 Mean (integer value) Mode Median
0 405 31 7 3 0.13 (0) 0 0 446
1 168 121 18 1 0.52 (1) 0 0 308
2 77 124 26 0.78 (1) 1 1 227
3 34 104 21 4 0.97 (1) 1 1 163
4 10 80 28 1 1.17 (1) 1 1 119
5 4 52 38 4 4 1.53 (2) 1 1 102
6 29 30 13 1.78 (2) 2 2 72
7 1 21 53 11 4 1.96 (2) 2 2 90
8 14 42 13 1.99 (2) 2 2 69
9 6 25 12 6 2.37 (2) 2 2 49
10 1 4 23 12 7 2.43 (2) 2 2 47
11 1 3 15 15 7 2.59 (3) 3 3 41
12 5 18 8 6 2.41 (2) 2 2 37
13 1 11 14 5 2.71 (3) 3 3 31
14 2 8 13 9 2.91 (3) 3 3 32
15 2 10 7 3.26 (3) 3 3 19
16 2 8 5 3.07 (3) 3 3 15
17 4 9 5 3.06 (3) 3 3 18
18 1 10 8 3.37 (3) 3 3 19
19 1 6 5 3.33 (3) 3 3 12
20 10 8 3.44 (3) 3 3 18
21 1 4 8 3.54 (4) 4 4 13
22 1 3 3 3.29 (3) 4 3 7
23 3 5 3.63 (4) 4 4 8
24 3 5 3.63 (4) 4 4 8
25 2 2 3.50 (4) 4 3.5 4
26 1 5 3.83 (4) 4 4 6
27 5 4.00 (4) 4 4 5
28 1 5 3.83 (4) 4 4 6
29 1 4.00 (4) N/A 4 1
30 1 4.00 (4) N/A 4 1
Patient totals 702 598 373 190 130 1993
DLQI, Dermatology Life Quality Index; GQ, Global Question.
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considering profile scores; however it is expected this
information will complement the process.
Several different approaches to interpretation of HRQoL
scores have been used, including population-based and
anchor-based techniques. In this study, the anchor-based
approach (Lydick and Epstein, 1993; Deyo and Patrick,
1995) was used as this is most appropriate for short, rel-
atively simple questionnaires. This technique involves relat-
ing the domain scores to a GQ. Anchor-based methods
have two requirements (Guyatt et al, 2002). First, the anchor
must be interpretable: the GQ was clearly understood by
participants. Second, there must be an appreciable asso-
ciation between the target and the anchor: this study dem-
onstrated a very close correlation between the DLQI and the
GQ. The use of the anchor technique in this study reflects
previous work relating to HRQoL in childhood and adult
asthma (Barber et al, 1996; Juniper et al, 1996a; Santanello
et al, 1999) and rhinoconjunctivitis (Juniper et al, 1996b).
In this study, we have used the anchoring GQ as the
basis for devising a ‘‘banded scale’’ of the total DLQI
scores. The banding system that we propose for adoption is
0–1, 2–5, 6–10, 11–20, 21–30 (k¼ 0.489). Although there
was an alternative set of bands that had a minimally higher k
coefficient (0.493), which differed only in where the line was
drawn between bands 2 and 3 (10–11 or 12–13), there are
other factors to take into consideration. The proposed set
puts DLQI scores of 11 and 12 into the higher band. DLQI
scores of 11 were more often correlated with GQ scores of
3 and 4, than was the case for DLQI scores of 10 (this can
be seen as a ‘‘step-up’’ in the graph in Fig 2). Furthermore,
in order to score 11 points on the DLQI an individual has to
score at least 2 (‘‘a lot’’) on one of the 10 questions. Hence,
on ‘‘common-sense’’ face value it seems more appropriate
to group DLQI scores of 11, and therefore scores of 12, into
the higher band. By having 11 and 12 in the higher band, the
proposed banding scale gives much more easily remem-
bered divisions, namely 0–1, 2–5, 6–10, 11–20, 21–30. It is
also easy to remember that, once a DLQI score goes above
10, then this equates to the skin condition having a ‘‘very
large effect’’ on skin-related QoL. Choosing a scale that is
easy to remember has major implications for the accept-
ability and appropriateness of the DLQI’s use in the routine
clinical setting.
There may be several reasons why a few patients re-
corded a high GQ score but a low DLQI score. One reason
may be that patients presenting with possible skin cancer
may reflect their worry in a high GQ score, but the questions
on the DLQI miss this factor.
The comparisons of overall responses between genders
did not reveal any significant differences. It has been re-
ported that males and females perceive their QoL to be
affected differently (Harlow et al, 2000; Wijnhoven et al,
2003) but this was not the case in this study. If there had
been significant differences, consideration would need to
have been given to proposing different bandings for males
and females.
Knowing the DLQI score in a patient may be helpful to
inform the clinician when taking critical management deci-
sions such as the initiation of systemic therapy in psoriasis,
acne or atopic eczema, or decisions concerning admission
for inpatient or intensive outpatient therapy. The DLQI score
may also be useful to inform decisions about the clinical
priority to be given to patients when resources are limited.
This study indicates that if the DLQI score is greater than 10,
the skin disease is having a very large effect on the patient’s
life. A DLQI score of greater than 10 would therefore gen-
erally be strong supportive evidence for the need for active
patient intervention. In the outpatient population studied,
15% of patients had a score 410 (11% 412). If the DLQI is
greater than 20 (only 3% of the population studied), this
Figure 2
Relationship between the Dermatology Life Quality Index (DLQI)
score and the mode, mean, and median of the Global Question
(GQ) score. The proposed banding scale of DLQI scores 0–1, 2–5, 6–
10, 11–20, 21–30 is also shown.
Table II. j coefﬁcients of agreement for separate possible sets
of bands of the DLQI scores
Assignment of DLQI scores into bands
j coefﬁcient
of agreementBand 0 Band 1 Band 2 Band 3 Band 4
0–1 2–5 6–12 13–20 21–30 0.493
0–1 2–5 6–12 13–22 23–30 0.490
0–1 2–5 6–10 11–20 21–30 0.489
0–1 2–5 6–10 11–22 23–30 0.486
DLQI, Dermatology Life Quality Index.
Table III. Proposed banding of the DLQI with the distribution
of GQ scores for the bands 0–1, 2–5, 6–10, 11–20, 21–30;




Totals (%)0 1 2 3 4
Band 0
(scores 0–1)
573 152 25 0 4 754 (38%)
Band 1
(scores 2–5)
125 360 113 9 4 611 (31%)
Band 2
(scores 6–10)
2 74 173 61 17 327 (16%)
Band 3
(scores 11–20)
2 12 60 103 65 242 (12%)
Band 4
(scores 21–30)
0 0 2 17 40 59 (3%)
Totals 702 598 373 190 130 1993
DLQI, Dermatology Life Quality Index; GQ, Global Question.
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indicates an extremely large effect on the patient’s life and
would generally indicate the need for very urgent, intensive
intervention. The application of banding to the DLQI scores
will allow harmonization, where appropriate, of treatment
strategies between clinicians.
The proposed banding accords well with data from pre-
vious studies describing average baseline DLQI scores in
cohorts of patients in whom active intervention was con-
sidered indicated. Examples in psoriasis include: the use of
cyclosporin (median DLQI¼ 11.0, Touw et al, 2001); alefacept
(mean DLQI¼ 11.3, Finlay et al, 2003); and admission for
therapy (mean DLQI¼13.9, Kurwa and Finlay, 1995). Exam-
ples in acne include the use of oral isotretinoin (DLQI¼9.2,
Newton et al, 1997). Examples in atopic eczema include the
use of UVB (mean DLQI¼10.8, Piletta et al, 1996).
Although it is possible for a clinician to gain an overall
view of a patient’s QoL by asking a single question, the use
of a more detailed questionnaire provides much richer detail
that allows the clinician both to address specific problems
experienced by a patient and to identify which aspects of
the patient’s life are most severely affected by their disease.
Intervention can therefore be directed more appropriately.
It is believed that the findings of this study will help der-
matologists to interpret DLQI scores and allow them to use
this data in their clinical decision taking on a routine basis.
Materials and Methods
This was an open, prospective study of outpatients with general
unselected skin diseases in a secondary-care setting. The DLQI, a
dermatology-specific instrument, was chosen to assess the mean-
ingfulness of scores against a single-item questionnaire (GQ) re-
cording the patients’ overall skin-related HRQoL. The study was
registered as an audit project with the Cardiff and Vale National
Health Service (NHS) Trust audit department and full ethical ap-
proval was obtained from the South East Wales Local Research
Ethics Committee. This clinical investigation was conducted ac-
cording to the Declaration of Helsinki principles. Approval was
given by the R&D Department and the Data Protection Department
of Cardiff and Vale NHS Trust. Permission was obtained from all the
dermatology consultants in Cardiff for their patients to be involved
in the study.
The majority of patients referred to UK hospital dermatology
departments by general practitioners are placed on an outpatient
WL. This is carried out after the referral letters are vetted by a
dermatology consultant. Patients may have to wait several months
before being seen by a dermatologist. In this study, patients were
selected from the dermatology outpatient WL (n¼ 3569) or from
patients seen in the clinic in the previous 2 mo (n¼ 523). From
these 4092 outpatients, 3834 met the inclusion criteria of being
aged 16 y and above and of having a skin condition, and they were
posted a study pack containing a personalized invitation letter, a
patient information sheet, questionnaires, and a freepost envelope.
Two weeks after the first mailing, a follow-up pack was sent to the
non-responders.
DLQI There are ten questions in the DLQI that ask the patient to
define how his/her skin disease has affected his/her HRQoL over
the last week (Fig 1). The sum of the scores provides a value be-
tween 0 (no involvement) and 30 (maximum impact on the HRQoL
of the patient). The questions are easily understood, with an av-
erage completion time of 2 min (Loo et al, 2003), and fit onto a
single side of A4 paper (30  21 cm). The DLQI measurement
properties have been established over the last 10 y (Lewis and
Finlay, 2004). Thus, the DLQI has the potential of becoming widely
accepted as an aid to treatment decision taking in routine clinical
practice. Although the DLQI has been partially psychometrically
tested (Lewis and Finlay, 2004), some properties of this instrument
have not yet been published.
GQ In order to examine the relationship between patients’ as-
sessment of their overall HRQoL and multi-dimensional DLQI
scores, a GQ was used (Salek et al, 1992; Khan, 1993; Hyland &
Sodergren, 1996).
‘‘Over the last week, how much has your skin problem affected
your life?’’
The five possible response categories were:
Extremely large effect on my life (allocated 4 points)
Very large effect on my life (3 points)
Moderate effect on my life (2 points)
A small effect on my life (1 point)
No effect at all (0 points)
The patient had to tick one of five corresponding boxes.
Both the DLQI and GQ were printed on light colored paper to
enhance response rate (Eiseman, 2000).
Dermatological conditions The patients were not asked for con-
sent to look at their referral letters or medical records as this may
have reduced the response rate. In order to describe the nature of
skin conditions that typically appear on this department’s outpa-
tient WL, a separate selection of 1108 referral letters for different
patients on the WL was made. These letters were analyzed by two
of the authors (A. Y. F. and C. L. T.) to determine each patient’s
probable dermatological diagnosis. One ‘‘main diagnosis’’ was re-
corded per referral letter. (In the case of more than one skin prob-
lem per patient, the diagnosis that had triggered the referral was
taken as the main dermatological diagnosis.)
Data processing and statistical analysis Data were entered and
processed using SPSS version 11.0 for Windows (George and
Mallery, 2002). A gender comparison was made using the Mann–
Whitney U test. The Spearman rank correlation coefficient was
used to examine the correlation between the DLQI scores and the
GQ scores. The mean, mode, and median of the GQ scores for
each DLQI score were used to devise separate sets of bands of the
DLQI scores and the k coefficient of agreement was calculated for
each set.
Additionally, for those patients whose GQ score majorly disa-
greed (by two or more bands) with that predicted from the devised
DLQI banding score, sub-score comparisons were made with
those patients whose GQ scores agreed with the DLQI banding.
We wish to thank Sister M. Chawla for her help and the patients for
contributing to the study.
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